5.4 Biomarker-guided treatment In the precision treatment strategy for gemcitabine resistance, biomarker guided treatment based on dynamic monitoring of RRM2 copy number based on ctDNA and multi-omics prediction models (such as the EXPLOR trial) provides a new paradigm for individualized intervention: Gemcitabine resistance, RRM2 gene copy number amplification drives resistance by accelerating deoxyribonucleotide triphosphate (dNTP) synthesis and enhancing DNA repair, while ctDNA-based liquid biopsy technology (such as ddPCR/NGS) can dynamically monitor the level of RRM2 amplification and track the evolution of resistant clones in real time
As a classical inducer of ferroptosis, erastin can inhibit the transcriptional activity of AR and its splice variants in vitro and in vivo
Macrophages and mast cells clear damaged tissue and cellular debris, while secreting proteins essential for wound contraction and overall tissue healing.[2][3] Research indicates that GHK-Cu may increase synthesis of collagen, elastin, and glycosaminoglycans.[1] Contraindications & Precautions GHK-Cu formulations are generally well-tolerated
Many growth signals, immune signals, and tissue repair signals are peptides too
The adult rat hippocampus contains primordial neural stem cells
Its use has been attributed to the rise in autism
